169 related articles for article (PubMed ID: 8595145)
1. Recent clinical advances with camptothecin analogues.
Slichenmyer WJ; Donehower RC
Cancer Treat Res; 1995; 78():29-43. PubMed ID: 8595145
[No Abstract] [Full Text] [Related]
2. Topoisomerase I inhibitors: topotecan and irenotecan.
Creemers GJ; Lund B; Verweij J
Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
[No Abstract] [Full Text] [Related]
3. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Slichenmyer WJ; Rowinsky EK; Grochow LB; Kaufmann SH; Donehower RC
Cancer Chemother Pharmacol; 1994; 34 Suppl():S53-7. PubMed ID: 7520844
[TBL] [Abstract][Full Text] [Related]
4. Clinical studies of camptothecin and derivatives.
Soepenberg O; Sparreboom A; Verweij J
Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
[No Abstract] [Full Text] [Related]
5. Topoisomerase I inhibitors: topotecan and irinotecan.
Jones SF; Burris HA
Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
[No Abstract] [Full Text] [Related]
6. Topoisomerase I inhibition: a new target or new missiles?
Verweij J; Schellens JH
Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
[No Abstract] [Full Text] [Related]
7. Irinotecan (CPT-11): pharmacology and clinical applications.
Masuda N; Kudoh S; Fukuoka M
Crit Rev Oncol Hematol; 1996 Sep; 24(1):3-26. PubMed ID: 8869796
[No Abstract] [Full Text] [Related]
8. Irinotecan hydrochloride.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(4):179-80, 184. PubMed ID: 12690622
[No Abstract] [Full Text] [Related]
9. Design, synthesis and development of novel camptothecin drugs.
Liew ST; Yang LX
Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
[TBL] [Abstract][Full Text] [Related]
10. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of topoisomerase I inhibitors in anticancer treatment.
Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
[TBL] [Abstract][Full Text] [Related]
12. The current status of irinotecan (CPT-11) in the United States.
Rothenberg ML
Ann N Y Acad Sci; 1996 Dec; 803():272-81. PubMed ID: 8993521
[No Abstract] [Full Text] [Related]
13. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Kim DK; Lee N
Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials using irinotecan.
Houghton PJ; Santana VM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
[No Abstract] [Full Text] [Related]
15. Current perspectives on camptothecins in cancer treatment.
Dancey J; Eisenhauer EA
Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345
[TBL] [Abstract][Full Text] [Related]
16. [Role of irinotecan in the treatment of small cell carcinoma].
Crinò L
Tumori; 2001; 87(6):A35-7. PubMed ID: 11995707
[No Abstract] [Full Text] [Related]
17. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan in colorectal cancer].
Pozzo C; Cassano A; Barone C
Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
[No Abstract] [Full Text] [Related]
20. [Irinotecan].
Yokoyama A
Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
